TY  - GEN
AU  - Mammatas,L H
AU  - Zandvliet,A S
AU  - Rovithi,M
AU  - Honeywell,R J
AU  - Swart,E L
AU  - Peters,G J
AU  - Menke-van der Houven van Oordt,C W
AU  - Verheul,H M W
TI  - Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study
SN  - 1432-0843
PY  - 2020///1117
KW  - Area Under Curve
KW  - Dose-Response Relationship, Drug
KW  - Drug Administration Schedule
KW  - Drug Monitoring
KW  - methods
KW  - Drug-Related Side Effects and Adverse Reactions
KW  - prevention & control
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neoplasms
KW  - drug therapy
KW  - Protein Kinase Inhibitors
KW  - administration & dosage
KW  - Pulse Therapy, Drug
KW  - Sorafenib
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Journal Article
UR  - https://doi.org/10.1007/s00280-020-04065-5
ER  -